Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
歌禮-B停止多項FXR激動劑ASC42臨床試驗及研究

2024-04-03T  
《公司業績》歌禮製藥全年虧損收窄至1.45億人民幣

2024-03-26T  
歌禮製藥-B在美國皮膚病學會年會上展示治療痤瘡藥物研究結果

2024-03-11T  
藥明系急瀉殃及同業 百濟神州及金斯瑞挫8%至9% 復星醫藥創逾十年低

2024-02-02T  
歌禮製藥-B完成治療痤瘡III期臨床試驗首例患者給藥

2024-01-24T  
醫藥板塊上揚 威高股份、中國中藥、綠葉、康方及宜明昂科升6%-11%

2024-01-09T  
歌禮製藥-B(01672.HK)早段曾升逾11% ASC41臨床試驗獲積極期中結果

2024-01-03T  
歌禮製藥-B(01672.HK)肝炎藥ASC41片劑臨床試驗獲積極期中結果

2024-01-03T  
歌禮製藥ASC40(地尼法司他)治療痤瘡III期臨床試驗

2023-12-05T  
歌禮製藥-B恩沃利單抗研究顯示乙肝表面抗原顯著下降

2023-11-13T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.